Sign in Subscribe
Class action lawsuits

Securities Lawsuit Filed Against Rocket Pharmaceuticals, Inc.

Strategic Insights

— 1 min read

Levi & Korsinsky, LLP, a prominent law firm specializing in securities litigation, has filed a class action securities lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). The lawsuit seeks to recover losses on behalf of Rocket investors who were allegedly adversely affected by securities fraud between February 27, 2025, and May 26, 2025. The complaint alleges that defendants provided false and misleading statements regarding the safety and clinical trial protocol of RP-A501, causing investors to purchase Rocket's securities at artificially inflated prices.

Key Takeaways:

  • The lawsuit was filed on behalf of Rocket investors who suffered losses due to alleged securities fraud between February 27, 2025, and May 26, 2025.
  • The complaint alleges that defendants provided false and misleading statements regarding the safety and clinical trial protocol of RP-A501.
  • Rocket amended the trial's protocol to introduce a novel immunomodulatory agent without disclosing this update to shareholders.
  • The price of Rocket's common stock declined dramatically after the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study due to a Serious Adverse Event (SAE) that resulted in a patient's death.
  • The stock price of Rocket declined from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, a decline of about 37% in a single trading day.
  • Investors who suffered losses during the relevant time frame have until August 11, 2025, to request appointment as lead plaintiff.
  • There is no cost or obligation to participate, and investors may be entitled to compensation without payment of any out-of-pocket costs or fees.

Statistics:

  • 37% decline in Rocket's stock price on May 27, 2025, after the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study.
  • $2.33 per share, the closing market price of Rocket's common stock on May 27, 2025.
  • $6.27 per share, the closing market price of Rocket's common stock on May 23, 2025.
  • 20 years, the length of time that Levi & Korsinsky has been securing hundreds of millions of dollars for aggrieved shareholders.
  • 7 years, the duration for which Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Sources:

  • Globe Newswire, "Levi & Korsinsky Notifies Investors in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit," July 17, 2025.

Read more